TC BioPharm (TCBP) said Wednesday it executed a non-binding letter of intent to acquire a commercial-stage ophthalmic pharmaceutical company in an all-stock transaction.
The target company has a US Food and Drug Administration-approved once-per-day drop to decrease intraocular pressure and a pipeline of development-stage assets in ophthalmology indications, TC said.
The company said it expects to execute the binding letter of intent in the next 2-3 weeks and close the acquisition in Q3 of 2025.
Shares of TC BioPharm were over 8% lower in recent trading.
Price: 1.78, Change: -0.16, Percent Change: -8.25
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.